The Global Fund has launched a web-based Price Reporting Mechanism. This enables recipients of Global Fund grants to provide data on the prices they have paid and the product quality and supplier performance they have received when using their grants for procurement purposes. The data on produce prices is then made publicly available so that anyone interested can compare who has paid how much for which products.
[The following Q&A regarding the pricing agreement was released on 6 April 2004 by the same four organizations as the above press release.]
[The following press release was issued on 6 April 2004 by the William J. Clinton Foundation, The Global Fund, UNICEF, and The World Bank.]
6 April 2004
New Agreements Aim to Make Lowest-Priced AIDS Drugs and Diagnostics Available to Hundreds of Thousands of Patients Throughout the Developing World
The Global Fund and three other organizations today announced ways in which grant recipients can obtain high quality antiretroviral drugs and diagnostics at very low prices that previously were only available to a few countries.
Something quite remarkable happened a few days ago. On Thursday 25 September, a simple and obvious proposal was made by Stephen Lewis, the passionate Canadian who serves as the UN Secretary-General's Special Envoy for HIV/AIDS in Africa. Speaking at a conference on AIDS in Nairobi, he said that Canada should issue a compulsory license to lift the patent protection that covers most anti-retroviral drugs (ARVs).
Richard Feachem, Executive Director of the Global Fund, provided some useful insights during a media conference call on 19 November 2002 organized by RESULTS and Health GAP (Global Access Project). Some quotes are as follows:
On the AIDS pandemic:
The Global Fund's third Board meeting, held in Geneva on 10-11October 2002, was, according to Executive Director Richard Feachem, "a huge improvement on the first two Board meetings," but it still left many participants frustrated when time ran out before the agenda was completed.